Compare Gilead Sciences, Inc. (GILD) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kyndryl Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Kyndryl Holdings Inc trades at $11.86 (market cap $2.49B). The key difference: Gilead Sciences, Inc. is far larger — about 73.1× Kyndryl Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kyndryl Holdings Inc for 36 Days on average.
| GILD | KD | |
|---|---|---|
Market Cap | $182.09B | $2.49B |
Volume | 4,960,247 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $155.80 | $29.76 |
52-Week Low | $116.74 | $10.59 |
Typical Hold Time | 111 Days | 36 Days |
Enterprise Value | $205.15B | $5.32B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Kyndryl (KD) trades at $11.88, up 3.48% today, with a bearish technical signal and mixed earnings. Revenue declined to $15.06B in 2025, but net income turned positive at $252M, marking a recovery from prior losses. The company is actively investing in AI, as highlighted by recent news of an AI innovation lab and acquisitions. Analyst consensus is mostly hold, with a $14.67 price target suggesting moderate upside.
The outlook hinges on AI-driven growth offsetting revenue pressures, but risks include high debt, competitive IT services market, and inconsistent earnings. Institutional sentiment is cautious, with weak technical trends near key support. Upside depends on execution of modernization contracts and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
